184 related articles for article (PubMed ID: 12165061)
1. The potential use of saliva to detect recurrence of disease in women with breast carcinoma.
Bigler LR; Streckfus CF; Copeland L; Burns R; Dai X; Kuhn M; Martin P; Bigler SA
J Oral Pathol Med; 2002 Aug; 31(7):421-31. PubMed ID: 12165061
[TBL] [Abstract][Full Text] [Related]
2. CA 15-3 and c-erbB-2 presence in the saliva of women.
Streckfus C; Bigler L; Dellinger T; Pfeifer M; Rose A; Thigpen JT
Clin Oral Investig; 1999 Sep; 3(3):138-43. PubMed ID: 10803125
[TBL] [Abstract][Full Text] [Related]
3. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.
Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT
Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088
[TBL] [Abstract][Full Text] [Related]
4. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma.
Streckfus C; Bigler L; Tucci M; Thigpen JT
Cancer Invest; 2000; 18(2):101-9. PubMed ID: 10705871
[TBL] [Abstract][Full Text] [Related]
5. Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men.
Streckfus C; Bigler L; Dellinger T; Dai X; Cox WJ; McArthur A; Kingman A; Thigpen JT
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Feb; 91(2):174-9. PubMed ID: 11174594
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptive usage and the expression of CA 15-3 and c-erbB-2 in the saliva of healthy women.
McIntyre R; Bigler L; Dellinger T; Pfeifer M; Mannery T; Streckfus C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1999 Dec; 88(6):687-90. PubMed ID: 10625851
[TBL] [Abstract][Full Text] [Related]
7. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
[TBL] [Abstract][Full Text] [Related]
8. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
[TBL] [Abstract][Full Text] [Related]
9. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
10. The expression of the c-erbB-2 receptor protein in glandular salivary secretions.
Streckfus CF; Bigler L; Dellinger T; Kuhn M; Chouinard N; Dai X
J Oral Pathol Med; 2004 Nov; 33(10):595-600. PubMed ID: 15482325
[TBL] [Abstract][Full Text] [Related]
11. The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of breast cancer in women: the results of a five-year translational research study.
Streckfus C; Bigler L
Adv Dent Res; 2005 Jun; 18(1):17-24. PubMed ID: 15998939
[TBL] [Abstract][Full Text] [Related]
12. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients.
Fehm T; Gebauer G; Jäger W
Breast Cancer Res Treat; 2002 Sep; 75(2):97-106. PubMed ID: 12243512
[TBL] [Abstract][Full Text] [Related]
14. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients.
Asgeirsson KS; Agrawal A; Allen C; Hitch A; Ellis IO; Chapman C; Cheung KL; Robertson JF
Breast Cancer Res; 2007; 9(6):R75. PubMed ID: 17976236
[TBL] [Abstract][Full Text] [Related]
15. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
17. [Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional clinical features and biomarkers].
Fodor J
Magy Onkol; 2009 Mar; 53(1):7-14. PubMed ID: 19318321
[TBL] [Abstract][Full Text] [Related]
18. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
Wu JT; Astill ME; Gagon SD; Bryson L
J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening.
Laidi F; Bouziane A; Errachid A; Zaoui F
Asian Pac J Cancer Prev; 2016; 17(1):335-9. PubMed ID: 26838233
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
